Alopecia

Deuruxolitinib 8 mg BID was found to be the most effective oral JAK inhibitor for severe alopecia areata in a new meta-analysis.

The trial evaluates ritlecitinib's efficacy for severe alopecia areata, utilizing innovative external placebo controls for enhanced patient outcomes.

An innovative artificial intelligence (AI) tool enhanced alopecia areata assessment and improved treatment adherence.

Among survey respondents, approximately 80% reported experiencing stigma, including feelings of embarrassment, negative judgment, or being treated differently, because of their condition.

The findings add confidence to the role of ritlecitinib as a treatment option for severe alopecia areata while pointing the way toward more personalized approaches.

Clonally expanded CD8+ T cells appear to play a causal role in the initiation and progression of alopecia areata.

Patients with alopecia universalis and alopecia totalis are at a particularly high risk of cardiovascular disease, a new study has found.

Hair and scalp disorders in patients with skin of color are frequently misdiagnosed, often due to educational gaps and premature diagnosis, with scalp biopsy proving more reliable than trichoscopy for accurate diagnosis.

The trial is one of 2 phase 3 studies of upadacitinib in patients with severe alopecia areata.

Janus kinase inhibitors can be paired with corticosteroids or used as monotherapy in the treatment of alopecia areata.

The research showed that certain females—but not males—were at a higher risk of anxiety and depression.

Investigators found that Janus kinase inhibitors were effective in a dose-dependent manner.

Racial and ethnic disparities are found among Asian individuals as they experience the highest lifetime incidence of alopecia areata, and Black individuals face a disproportionately higher risk of anxiety disorders associated with the condition.

The most-read alopecia articles include topics on Janus kinase inhibitors, new therapeutic strategies, health-related quality of life measurements, potential links to the COVID-19 vaccine, and disease pathogenesis.

Deuruxolitinib showed significant efficacy and safety in hair regrowth stimulation among adult patients with alopecia areata, particularly in those with moderate to severe hair loss.

Patients with treatment-resistant central centrifugal cicatricial alopecia saw improvement in symptoms and gene expression, suggesting the potential of metformin as a new treatment option.

Low-dose oral minoxidil has been agreed upon by an international expert panel as an effective treatment for various hair loss conditions, such as alopecia, with guidelines provided for safe and effective use.

New and in-the-pipeline Janus kinase (JAK) inhibitors have the potential to make huge differences in the lives of patients with this psychologically distressing autoimmune disease.

Kristen Whitney, DO, FAAD, dermatologist at Allegheny Health Network, explored the intricate management of alopecia areata, often in tandem with other autoimmune conditions while emphasizing the significance of innovative medications and diagnostic tools, such as dermoscopy, in enhancing patient outcomes.

Kristen Whitney, DO, FAAD, dermatologist at Allegheny Health Network, highlighted recent breakthroughs in treating alopecia areata, focusing on the effectiveness of Janus kinase inhibitors and the ongoing challenges related to insurance coverage and patient access.

Alopecia areata was more likely to develop in patients with inflammatory bowel disease (IBD) who were taking anti–tumor necrosis factor (TNF) therapy at the onset of the condition.

Alopecia areata is more prevalent in Hispanic, Asian/Pacific Islander, and Black children than in non-Hispanic White children, with some Asian subgroups having a higher risk compared with those of Chinese ethnicity.

Alopecia areata and asthma are strongly linked, particularly through the inflammatory protein IL-33, suggesting a shared biological pathway and potential for targeted treatments like dupilumab.

Upadacitinib, a drug used to treat atopic dermatitis (AD), may potentially induce alopecia areata, a case study suggests.

Alopecia areata is linked to specific trace elements, serum metabolites, and inflammatory factors, according to a genetic analysis, suggesting potential new treatment and prevention strategies.